Trial Profile

A Phase I, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HRS-1167 (Primary)
Indications Advanced breast cancer; Male breast cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
Focus Adverse reactions
Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

15 Apr 2025 Planned End Date changed from 31 Dec 2024 to 31 Dec 2026.
15 Apr 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2026.
04 Jun 2024 Results (As of Nov 20, 2023, n=40) assessing safety and efficacy of HRS-1167 (M9466) in patients with advanced solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com